Добавил:
ivanov666
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Роль адипокинов, гормонов гастропанкреодуоденальной зоны в развитии инсулинорезистентности и восстановлении нормальной толерантности к глюкозе у больн
.pdf
49. Fehmann H.
C., Göke R., Göke B. Cell and molecular biology of
the incretin hormones glucagon-like peptide-I and glucose-dependent
insulin releasing polypeptide // Endocr Rev. 1995. Vol. 16, №
3.
P. 390—410.
50. Fernandez-Robredo P., Recalde S., Hernandez M. et al. Novel
association of high c-reactive protein levels and a69s at risk alleles in wet
age-related macular degeneration women // Front Immunol. 2018. Vol. 9.
P. 1862.
51. Ferrante A.
W. Jr. Macrophages, fat, and the emergence of immu-
nometabolism // J Clin Invest. 2013. Vol. 123, № 12. P. 4992—4993.
52. Fisman E.
Z., Tenenbaum A. Adiponectin: a manifold therapeutic
target for metabolic syndrome, diabetes, and coronary disease? // Cardiovasc. Diabetol. 2014. Vol. 13. P. 103.
53. Flint A., Raben A., Astrup A. et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans// J Clin Invest.
1998. Vol. 101, №
3. P. 515—520.
54. Fonseca V. A., Zinman B., Nauck M. A. et al. Confronting the type
2 diabetes epidemic: the emerging role of incretin-based therapies // Am J
Med. 2010. Vol. 123, №
55. Freitas Lima L.
7. P. 2—10.
C., Braga V. A., do Socorro de França Silva M. et al.
Adipokines, diabetes and atherosclerosis: an inflammatory association //
Front Physiol. 2015. Vol. 6. P. 304.
56. Gabe M.
B. N., van der Velden W. J. C., Smit F. X. Molecular
interactions of full-length and truncated GIP peptides with the GIP receptor — A comprehensive review // Peptides. 2020. Vol. 125. P. 170224.
57. Gahagan S. Development of eating behavior: biology and context //
J Dev Behav Pediatr. 2012. Vol. 33, №
58. Gainsford T., Willson T.
3. P. 261—71.
A., Metcalf D. et al. Leptin can induce
proliferation, differentiation, and functional activation of hemopoietic
cells // Proc. Natl. Acad. Sci. U.
S. A. 1996. Vol. 93, № 25. P. 14564—
14568.
59. Gautron L. The Phantom Satiation Hypothesis of Bariatric Surgery // Front Neurosci. 2021. Vol. 15. P. 626085.
60. Gómez-Banoy N., Guseh J.
S., Li G. et al. Adipsin preserves beta
cells in diabetic mice and associates with protection from type 2 diabetes
in humans // Nat Med. 2019. Vol. 25, №
11. P. 1739—1747.
61. Gruzdeva O., Borodkina D., Uchasova E. et al. Leptin resistance:
underlying mechanisms and diagnosis // Diabetes Metab Syndr Obes.
2019. Vol. 12. P. 191—198.
91
62. Hall J.
morbid obesity. The Adelaide Study // Ann Surg. 1990. Vol. 211, №
C., Watts J. M., O'Brien P. E. et al. Gastric surgery for
4.
P. 419—427.
63. Højberg P.
V., Zander M., Vilsbøll T. et al. Near normalisation of
blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes // Diabetologia.
2008. Vol. 51, №
64. Holst J.
4. P. 632—640.
J. The incretin system in healthy humans: The role of GIP
and GLP-1 // Metabolism. 2019. Vol. 96. P. 46—55.
65. Hotamisligil G.
S., Peraldi P., Budavari A. et al. IRS-1-mediated
inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and
obesity-induced insulin resistance // Science. 1996. Vol. 271, №
5249.
P. 665—668.
66. Hutch C.
R., Sandoval D. The Role of GLP-1 in the Metabolic
Success of Bariatric Surgery // Endocrinology. 2017. Vol. 158, № 12.
P. 4139—4151.
67. Inui A., Asakawa A., Bowers C.
Y. et al. Ghrelin, appetite, and
gastric motility: the emerging role of the stomach as an endocrine organ //
FASEB J. 2004. Vol. 18, №
3. P. 439—456.
68. Jørgensen N. B., Jacobsen S. H., Dirksen C. et al. Acute and longterm effects of Roux-en-Y gastric bypass on glucose metabolism in
subjects with Type 2 diabetes and normal glucose tolerance // Am J Physiol Endocrinol Metab. 2012. Vol. 303, №
69. Jung U.
J., Choi M. S. Obesity and its metabolic complications:
1. P. 122—131.
the role of adipokines and the relationship between obesity, inflammation,
insulin resistance, dyslipidemia and nonalcoholic fatty liver disease // Int
J Mol Sci. 2014.Vol. 15, №
4. P. 6184—6223.
70. Karmali S., Johnson Stoklossa C., Sharma A. et al. Bariatric sur-
gery: a primer // Can Fam Physician. 2010. Vol. 56, №
71. Kim M.
K., Lee H. C., Lee S. H. et al. The difference of glucostatic
9. P. 873—879.
parameters according to the remission of diabetes after Roux-en-Y gastric
bypass // Diabetes Metab Res Rev. 2012. Vol. 28, №
72. Klimontov V.
V., Bulumbaeva D. M., Bgatova N. P. et al. Serum
5. P. 439—446.
adipokine concentrations in patients with type 2 diabetes: the relationships with distribution, hypertrophy and vascularization of subcutaneous
adipose tissue // Diabetes mellitus. 2019. Vol. 22, №
4. P. 336—347.
73. Knop F. K., Vilsbøll T., Højberg P. V. et al. Reduced incretin
effect in type 2 diabetes: cause or consequence of the diabetic state? //
Diabetes. 2007. Vol. 56, №
8. P. 1951—1959.
92
74. Kohei K. Pathophysiology of type 2 diabetes and its treatment
policy // Jpn Med Assoc J. 2010. Vol. 53, №
1. P. 41—46.
75. Könner A. C., Klöckener T., Brüning J. C. Control of energy homeostasis by insulin and leptin: targeting the arcuate nucleus and beyond //
Physiol Behav. 2009. Vol. 97, №
76. Koopman A.
D. M., Rutters F., Rauh S. P. et al. Incretin responses
5. P. 632—638.
to oral glucose and mixed meal tests and changes in fasting glucose levels
during 7 years of follow-up: The Hoorn Meal Study // PLoS One. 2018.
Vol. 13, №
Gastric Banding // Obes Surg. 1991. Vol. 1, №
1. P. e0191114.
77. Kuzmak L.
I. A Review of Seven Years' Experience with Silicone
4. P. 403—408.
78. Laferrère B., Teixeira J., McGinty J. et al. Effect of weight loss
by gastric bypass surgery versus hypocaloric diet on glucose and incretin
levels in patients with type 2 diabetes // J Clin Endocrinol Metab. 2008.
Vol. 93, №
potential therapeutic strategy // Atherosclerosis. 2014. Vol. 233, №
7. P. 2479—2485.
79. Lim S., Quon M.
J., Koh K. K. Modulation of adiponectin as a
2.
P. 721—728.
80. Lindqvist A., Shcherbina L., Fischer A.
T. et al. Ghrelin Is a Regu-
lator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice //
Front Endocrinol (Lausanne). 2017. Vol. 8. P. 135.
81. Litvinova L.
S., Kirienkova E. V., Mazunin I. O. et al. Insulin resis-
tance pathogenesis in metabolic obesity // Biomed Khim. 2015. Vol. 61,
P. 70—82.
82. Lloret A., Monllor P., Esteve D. et al. Obesity as a Risk Factor for
Alzheimer's Disease: Implication of Leptin and Glutamate // Front Neurosci. 2019. Vol. 13. P. 508.
83. Lo J.
improves β cell function in diabetes // Cell. 2014. Vol. 158, №
84. Lobato C.
C., Ljubicic S., Leibiger B. et al. Adipsin is an adipokine that
1. P. 41—53.
B., Pereira S. S., Guimarães M. et al. A Potential Role
for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia //
Front Endocrinol (Lausanne). 2020. Vol. 11. P. 608248.
85. Lord G. M., Matarese G., Howard J. K. et al. Leptin modulates
the T-cell immune response and reverses starvation-induced immunosuppression // Nature. 1998. Vol. 394, №
6696. P. 897—901.
86. Lu J., Zhao J., Meng H. et al. Adipose Tissue-Resident Immune
Cells in Obesity and Type 2 Diabetes // Front Immunol. 2019. Vol. 10.
P. 1173.
93
87. Lu Z., Li Y., Song J. Characterization and Treatment of Inflammation and Insulin Resistance in Obese Adipose Tissue // Diabetes Metab
Syndr Obes. 2020. Vol. 13. P. 3449—3460.
88. Lumeng C.
N., Bodzin J. L., Saltiel A. R. Obesity induces a pheno-
typic switch in adipose tissue macrophage polarization // J Clin Invest.
2007. Vol. 117, №
1. P. 175—184.
89. Lumeng C. N., Saltiel A. R. Inflammatory links between obesity
and metabolic disease // J Clin Invest. 2011. Vol. 121, №
6. P. 2111—
2117.
90. Malin S.
K., Samat A., Wolski K. et al. Improved acylated ghrelin
suppression at 2 years in obese patients with type 2 diabetes: effects of
bariatric surgery vs standard medical therapy // Int J Obes (Lond). 2014.
Vol. 38, №
3. P. 364—370.
91. Margetic S., Gazzola C., Pegg G. G. et al. Leptin: a review of its
peripheral actions and interactions // Int J Obes Relat Metab Disord. 2002.
Vol. 26, №
11. P. 1407—1433.
92. Mark A. L., Correria M.L, Rahmouni K., Haynes W. G. Selective
leptin resistance: a new concept in leptin physiology with cardiovascular
implications // J Hyper 2002 Vol. 20. P. 1245—1250.
93. Martin B., Lopez de Maturana R., Brenneman R. et al. Class II G
protein-coupled receptors and their ligands in neuronal function and protection // Neuromolecular Med. 2005. Vol. 7, №
1-2. P. 3—36.
94. Martos-Rus C., Katz-Greenberg G., Lin Z. et al. Macrophage and
adipocyte interaction as a source of inflammation in kidney disease // Sci
Rep. 2021. Vol. 11, №
1. P. 2974.
95. Matzko M. E., Argyropoulos G., Wood G. C. et al. Association of
ghrelin receptor promoter polymorphisms with weight loss following
Roux-en-Y gastric bypass surgery // Obes Surg. 2012. Vol. 22, №
5.
P. 783—790.
96. Mayo K.
E., Miller L. J., Bataille D. et al. International Union of
Pharmacology. XXXV. The glucagon receptor family // Pharmacol Rev.
2003. Vol. 55, №
97. Meier J.
1. P. 167—194.
J., Gallwitz B., Kask B. et al. Stimulation of insulin se-
cretion by intravenous bolus injection and continuous infusion of gastric
inhibitory polypeptide in patients with type 2 diabetes and healthy control
subjects // Diabetes. 2004. Vol. 53. P. 220—224.
98. Mulvihill E.
E., Drucker D. J. Pharmacology, physiology, and
mechanisms of action of dipeptidyl peptidase-4 inhibitors // Endocr Rev.
2014. Vol. 35, №
6. P. 992—1019.
94
99. Naka T., Nishimoto N., Kishimoto T. The раrаdigm оf IL-6:
frоm bаsiс sсienсe tо mediсine // Аrthritis. Res. 2002. Vol. 4, №
3.
P. 233—242.
100. Nannipieri M., Baldi S., Mari A. et al. Roux-en-Y gastric bypass
and sleeve gastrectomy: mechanisms of diabetes remission and role of gut
hormones // J Clin Endocrinol Metab. 2013. Vol. 98, №
11. P. 4391—
4399.
101. Nauck M.
A., Heimesaat M. M., Orskov C. et al. Preserved
incretin activity of glucagon-like peptide 1 [7—36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus // J Clin Invest. 1993. Vol. 91, №
102. Nauck M.
A., Homberger E., Siegel E. G. Incretin effects of inc-
1. P. 301—307.
reasing glucose loads in man calculated from venous insulin and C-peptide
responses // J Clin Endocrinol Metab. 1986. Vol. 63, №
103. Nielsen S.
T., Janum S., Krogh-Madsen R. et al. The incretin
2. P. 492—498.
effect in critically ill patients: a case-control study // Crit Care. 2015.
Vol. 19. P. 402.
104. O'Brien P.
E., McPhail T., Chaston T. B. et al. Systematic review
of medium-term weight loss after bariatric operations // Obes Surg. 2006.
Vol. 16, №
8. P. 1032—1040.
105. Oguntibeju O. Pathophysiology and Complications of Diabetes
Mellitus // BoD-Books on Demand. Croatia, 2012.
106. Okada-Iwabu M., Yamauchi T., Iwabu M. et al. A small-molecu-
le AdipoR agonist for type 2 diabetes and short life in obesity // Nature.
2013. Vol. 503, №
107. O'Neil P.
7477. P. 493—499.
M., Birkenfeld A. L., McGowan B. et al. Efficacy and
safety of semaglutide compared with liraglutide and placebo for weight
loss in patients with obesity: a randomised, double-blind, placebo and
active controlled, dose-ranging, phase 2 trial // Lancet. 2018. Vol. 392,
10148. P. 637—649.
№
108. Ozcan L., Ergin A.
S., Lu A. et al. Endoplasmic reticulum stress
plays a central role in development of leptin resistance // Cell Metab.
2009. Vol. 9, №
109. Parfitt A.
1. P. 35—51.
M., Pødenphant J., Villanueva A. R. et al. Metabolic
bone disease with and without osteomalacia after intestinal bypass surgery: a bone histomorphometric study // Bone. 1985. Vol. 6, №
4.
P. 211—220.
95
110. Parker B.
A., Doran S., Wishart J. et al. Effects of small intes-
tinal and gastric glucose administration on the suppression of plasma
ghrelin concentrations in healthy older men and women // Clin Endocrinol
(Oxf). 2005. Vol. 62, №
111. Paz-Filho G.
5. P. 539—546.
J., Volaco A., Suplicy H. L. et al. Decrease in leptin
production by the adipose tissue in obesity associated with severe metabolic syndrome // Arq Bras Endocrinol Metabol. 2009. Vol. 53, №
9.
P. 1088—1095.
112. Peng X., Li L., Zhang M. et al. Sodium-Glucose Cotransporter 2
Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion
Handling and Mitochondrial Dysfunction // Front Physiol. 2020. 11:912.
113. Philip J., Fernandez C.
Meglitinides // Curr Drug Saf. 2021. Vol. 16, №
J. Efficacy and Cardiovascular Safety of
2. P. 207—216.
114. Piero M., Nzaro G., Njagi J. Diabetes mellitus-a devastating me-
tabolic disorder // Asian J Biomed Pharm Sci. 2015. Vol. 5, №
115. Poher A.
L., Tschöp M. H., Müller T. D. Ghrelin regulation of
40. P. 1.
glucose metabolism // Peptides. 2018. Vol. 100. P. 236—242.
116. Pories W.
J., Flickinger E. G., Meelheim D. et al. The effective-
ness of gastric bypass over gastric partition in morbid obesity: consequence of distal gastric and duodenal exclusion // Ann Surg. 1982. Vol. 196,
№
4. P. 389—99.
117. Porsche C.
in adipose tissue T cell exhaustion // JCI Insight. 2021. Vol. 6, №
E., Delproposto J. B., Geletka L. et al. Obesity results
8.
P. e139793.
118. Pryor R., Cabreiro F. Repurposing metformin: an old drug with
new tricks in its binding pockets // Biochem J. 2015. Vol. 471, №
3.
P. 307—22.
119. Recinella L., Orlando G., Ferrante C. et al. Adipokines: New
Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and
Cardiovascular Diseases // Front Physiol. 2020. Vol. 11. P. 578966.
120. Rehfeld J.
Concept // Front Endocrinol (Lausanne). 2018. Vol. 16, №
121. Ridker P.
F. The Origin and Understanding of the Incretin
9. P. 387.
M. High-sensitivity C-reactive protein: potential adjunct
for global risk assessment in the primary prevention of cardiovascular
disease // Circulation. 2001.Vol. 103, №
13. P. 1813—1818. doi:10.1161/
01.cir.103.13.1813.
122. Ridker P.
M. Informative Neutral Studies Matter — Why the
Targeting Inflammation With Salsalate in Cardiovascular Disease
(TINSAL-CVD) Trial Deserves Our Attention // JAMA Cardiol. 2016.
Vol. 1, №
4. P. 423—424.
96
123. Ruаn H., Dоng L.
insulin tаrget tissues // J Mоl. Сell Biоl. 2016. Vol. 8, №
124. Scheid M.
P., Sweeney G. The role of adiponectin signaling in
Q. Аdiроneсtin signаling аnd funсtiоn in
2. Р. 101—119.
metabolic syndrome and cancer // Rev Endocr Metab Disord. 2014.
Vol. 15, №
2. P.157—167.
125. Segal K.
R., Landt M., Klein S. Relationship between insulin sen-
sitivity and plasma leptin concentration in lean and obese men // Diabetes.
1996. Vol. 45, №
7. P. 988—991.
126. Seufert J. Leptin effects on pancreatic beta-cell gene expression
and function // Diabetes. 2004. Vol. 53, №
1. P. 152—158.
127. Shibue K., Yamane S., Harada N. et al. Fatty acid-binding pro-
tein 5 regulates diet-induced obesity via GIP secretion from enteroendocrine K cells in response to fat ingestion // Am J Physiol Endocrinol Metab. 2015. Vol. 308, №
128. Skyler J.
7. P. 583—591.
S., Bakris G. L., Bonifacio E. et al. Differentiation of
Diabetes by Pathophysiology, Natural History, and Prognosis // Diabetes.
2017. Vol. 66, №
129. Song N.
2. P. 241—255.
J., Kim S., Jang B. H. et al. Small Molecule-Induced
Complement Factor D (Adipsin) Promotes Lipid Accumulation and Adipocyte Differentiation // PLoS One. 2016. Vol. 11, №
130. Spiegelman B.
M., Hotamisligil G. S. Through thick and thin:
wasting, obesity, and TNF alpha // Cell. 1993. Vol. 73, №
131. Stephens J.
M., Lee J., Pilch P. F. Tumor necrosis factor-alpha-
9. P. e0162228.
4. P. 625—627.
induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss
of insulin receptor substrate-1 and GLUT4 expression without a loss of
insulin receptor-mediated signal transduction // J Biol Chem. 1997.
Vol. 272, №
132. Sugerman H.
2. P. 971—976.
J., Starkey J. V., Birkenhauer R. A randomized pro-
spective trial of gastric bypass versus vertical banded gastroplasty for
morbid obesity and their effects on sweets versus non-sweets eaters //
Ann Surg. 1987. Vol. 205, №
133. Sundbom M., Holdstock C., Engström B.
6. P. 613—24.
E. et al. Early changes
in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve
functionality? // Obes Surg. 2007.Vol. 17, №
134. Swarbrick M.
M., Havel P. J. Physiological, pharmacological,
3. P. 304—10.
and nutritional regulation of circulating adiponectin concentrations in
humans // Metab. Syndr. Relat. Disord. 2008. Vol. 6, №
2. P. 87—102.
97
135. Tabassum R., Mia A.
R., Reza-Ul-Haq K. M. et al. C-reactive
Protein Level in Type-2 Diabetic Patients Attending Mymensingh Medical College Hospital // Mymensingh. Mymensingh Med J. 2017. Vol. 26,
1. P. 56—60.
№
136. Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, im-
munity, and disease // Cold Spring Harb Perspect Biol. 2014. Vol. 6, №
10.
P. a016295.
137. Taylor E.
mation, and autoimmunity // Clin Sci (Lond). 2021. Vol. 135, №
B. The complex role of adipokines in obesity, inflam-
6.
P. 731—752.
138. Thon M., Hosoi T., Ozawa K. Possible Integrative Actions of
Leptin and Insulin Signaling in the Hypothalamus Targeting Energy
Homeostasis // Front Endocrinol (Lausanne). 2016. Vol. 7. P. 138.
139. Thorp A.
A., Schlaich M. P. Relevance of Sympathetic Nervous
System Activation in Obesity and Metabolic Syndrome // J Diabetes Res.
2015. Vol. 2015. P. 341583.
140. Tong J., D'Alessio D. Give the receptor a brake: slowing gastric
emptying by GLP-1 // Diabetes. 2014. Vol. 63, №
141. Tosello-Trampont A., Surette F.
A., Ewald S. E. et al. Immunore-
2. P. 407—409.
gulatory Role of NK Cells in Tissue Inflammation and Regeneration //
Front Immunol. 2017. Vol. 8. P. 301.
142. Turner R.
C., Cull C. A., Frighi V. et al. Glycemic control with
diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes
mellitus: progressive requirement for multiple therapies (UKPDS 49). UK
Prospective Diabetes Study (UKPDS) Group // JAMA. 1999. Vol. 281,
21.
№
143. Usdin T.
B., Mezey E., Button D. C. et al. Gastric inhibitory poly-
peptide receptor, a member of the secretin-vasoactive intestinal peptide
receptor family, is widely distributed in peripheral organs and the brain //
Endocrinology. 1993. Vol. 133, № 1. P. 2861—2870.
144. Van de Voorde, J., Pauwels B., Boydens, C. et al. Adipocy-
tokines in relation to cardiovascular disease // Metab. Clin. Vol. 62, №
11.
P. 1513—1521.
145. Vasilenko M.
A., Kirienkova E. V., Skuratovskaia D. A. et al. The
role of production of adipsin and leptin in the development of insulin
resistance in patients with abdominal obesity // Dokl Biochem Biophys.
2017. Vol. 475, №
1. P. 271—276.
98
146. Villar H.
V., Fender H. R., Rayford P. L. et al. Suppression of
gastrin release and gastric secretion by gastric inhibitory polypeptide (GIP)
and vasoactive intestinal polypeptide (VIP) // Ann Surg. 1976. Vol. 184,
№
1. P. 97—102.
147. Walker E., Elman M., Takemoto E.
E. Bariatric surgery among
medicare subgroups: short- and long-term outcomes // Obesity (Silver
Spring). 2019. Vol. 27, №
11. P. 1820—1827.
148. Wang W., Cheng Z., Wang Y. et al. Role of Bile Acids in Bariat-
ric Surgery // Front Physiol. 2019. Vol. 10. P. 374.
149. Wang W., Lo A.
treatments // Int J Mol Sci. 2018. Vol. 19, №
150. Wascher T.
C. Diabetic retinopathy: pathophysiology and
6. P. 1—14.
C., Lindeman J. H., Sourij H. et al. Chronic TNF-α
neutralization does not improve insulin resistance or endothelial function
in "healthy" men with metabolic syndrome // Mol Med. 2011. Vol. 17,
№
3-4. P. 189—93.
151. Werner E.
D., Lee J., Hansen L. et al. Insulin resistance due to
phosphorylation of insulin receptor substrate-1 at serine 302 // J Biol
Chem. 2004. Vol. 279, №
152. West G.
M., Willard F. S., Sloop K. W. et al. Glucagon-like pep-
34. P. 35298—35305.
tide-1 receptor ligand interactions: structural cross talk between ligands
and the extracellular domain // PLoS One. 2014. Vol. 9, №
153. Wilson R., Aminian A., Tahrani A.
A. Metabolic surgery: A clini-
9. P. e105683.
cal update // Diabetes Obes Metab. 2021. Vol. 1. P. 63—83.
154. Wittgrove A.
C., Clark G. W., Tremblay L. J. Laparoscopic
Gastric Bypass, Roux-en-Y: Preliminary Report of Five Cases // Obes
Surg. 1994. Vol. 4, №
155. Wondafrash D.
4. P. 353—357.
Z., Nire'a A. T., Tafere G. G. et al. Thioredoxin-
Interacting Protein as a Novel Potential Therapeutic Target in Diabetes
Mellitus and Its Underlying Complications // Diabetes Metab Syndr Obes.
2020. Vol. 7, №
13. P. 43—51.
156. Xu L., Kitade H., Ni Y. et al. Roles of Chemokines and Chemo-
kine Receptors in Obesity-Associated Insulin Resistance and Nonalcoholic
Fatty Liver Disease // Biomolecules. 2015. Vol. 5, №
3. P. 1563—1579.
157. Yamauchi T., Kamon J., Waki H. et al. The fat-derived hormone
adiponectin reverses insulin resistance associated with both lipoatrophy
and obesity // Nat Med. 2001. Vol. 7, №
8. P. 941—946.
158. Yanagimachi T., FujitaY., Takeda, Y. et al. Pancreatic glucose-
dependent insulinotropic polypeptide (GIP) (1—30) expression is upregu-
99
l
ated in diabetes and PEGylated GIP(1—30) can suppress the progression
of low-dose-STZ-induced hyperglycaemia in mice // Diabetologia. 2016.
Vol. 59, №
3. P. 533—541.
159. Zhang Y., Proenca R., Maffei M. et al. Positional cloning of the
mouse obese gene and its human homologue // Nature. 1994. Vol. 372,
6505. P. 425—432.
№
160. Zhang, Y., Yang, X., Bian, F. et al. TNFα promotes early atheros-
clerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-κB and PPAR-γ // J. Mol. Cell. Cardiol. 2014. Vol. 72.
P. 85—94.
161. Zhou J., Hao Z., Irwin N. et al. Gastric inhibitory polypeptide
(GIP) is selectively decreased in the roux-limb of dietary obese mice after
RYGB surgery // PLoS One. 2015. Vol. 10, №
8. P. e0134728.
162. Zhou Q., Ge Q., Ding Y. et al. Relationship between serum adip-
sin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance // J Diabetes Investig. 2018. Vol. 9,
5. P. 1128—1134.
№
Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]